Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

GENE:

BCL2 (B-cell CLL/lymphoma 2)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related tests:

‹

›

BCL2 expression + MYC expression	Diffuse Large B Cell Lymphoma	BCL2 expression + MYC expression	Diffuse Large B Cell Lymphoma	chidamide Sensitive: A1 - Approval chidamide Sensitive : A1	chidamide Sensitive: A1 - Approval chidamide Sensitive : A1
MYC rearrangement + BCL2 rearrangement + BCL6 rearrangement	Diffuse Large B Cell Lymphoma	MYC rearrangement + BCL2 rearrangement + BCL6 rearrangement	Diffuse Large B Cell Lymphoma	lisocabtagene maraleucel Sensitive: A2 - Guideline lisocabtagene maraleucel Sensitive : A2	lisocabtagene maraleucel Sensitive: A2 - Guideline lisocabtagene maraleucel Sensitive : A2
MYC rearrangement + BCL2 rearrangement	Diffuse Large B Cell Lymphoma	MYC rearrangement + BCL2 rearrangement	Diffuse Large B Cell Lymphoma	lisocabtagene maraleucel Sensitive: A2 - Guideline lisocabtagene maraleucel Sensitive : A2	lisocabtagene maraleucel Sensitive: A2 - Guideline lisocabtagene maraleucel Sensitive : A2
BCL2 elevation + IGH elevation	Follicular Lymphoma	BCL2 elevation + IGH elevation	Follicular Lymphoma	rituximab Resistant: B - Late Trials rituximab Resistant : B	rituximab Resistant: B - Late Trials rituximab Resistant : B
MYC overexpression + BCL2 overexpression	Diffuse Large B Cell Lymphoma	MYC overexpression + BCL2 overexpression	Diffuse Large B Cell Lymphoma	ibrutinib Sensitive: B - Late Trials ibrutinib Sensitive : B	ibrutinib Sensitive: B - Late Trials ibrutinib Sensitive : B
MYC rearrangement + BCL2 rearrangement	Diffuse Large B Cell Lymphoma	MYC rearrangement + BCL2 rearrangement	Diffuse Large B Cell Lymphoma	lenalidomide Sensitive: B - Late Trials lenalidomide Sensitive : B	lenalidomide Sensitive: B - Late Trials lenalidomide Sensitive : B
BCL2 overexpression	Multiple Myeloma	BCL2 overexpression	Multiple Myeloma	venetoclax Sensitive: B - Late Trials venetoclax Sensitive : B	venetoclax Sensitive: B - Late Trials venetoclax Sensitive : B
BCL2 overexpression + MYC overexpression	Diffuse Large B Cell Lymphoma	BCL2 overexpression + MYC overexpression	Diffuse Large B Cell Lymphoma	ibrutinib Sensitive: B - Late Trials ibrutinib Sensitive : B	ibrutinib Sensitive: B - Late Trials ibrutinib Sensitive : B
BCL2 expression	Diffuse Large B Cell Lymphoma	BCL2 expression	Diffuse Large B Cell Lymphoma	venetoclax + obinutuzumab Sensitive: C2 – Inclusion Criteria venetoclax + obinutuzumab Sensitive : C2	venetoclax + obinutuzumab Sensitive: C2 – Inclusion Criteria venetoclax + obinutuzumab Sensitive : C2
BCL2 expression	Acute Myelogenous Leukemia	BCL2 expression	Acute Myelogenous Leukemia	venetoclax Sensitive: C2 – Inclusion Criteria venetoclax Sensitive : C2	venetoclax Sensitive: C2 – Inclusion Criteria venetoclax Sensitive : C2
BCL2 positive	Diffuse Large B Cell Lymphoma	BCL2 positive	Diffuse Large B Cell Lymphoma	venetoclax Sensitive: C2 – Inclusion Criteria venetoclax Sensitive : C2	venetoclax Sensitive: C2 – Inclusion Criteria venetoclax Sensitive : C2
MYC rearrangement + BCL2 rearrangement + BCL6 rearrangement	Lymphoma	MYC rearrangement + BCL2 rearrangement + BCL6 rearrangement	Lymphoma	lisocabtagene maraleucel Sensitive: C2 – Inclusion Criteria lisocabtagene maraleucel Sensitive : C2	lisocabtagene maraleucel Sensitive: C2 – Inclusion Criteria lisocabtagene maraleucel Sensitive : C2